New developments in antitumor anthracyclines
References (35)
- et al.
Adriamycin (14-hydroxydaunorubicin) an antitumor antibiotic
Tetrahedron Lett.
(1969) - et al.
Approche de la synthèse d'anthracyclines oligosaccharidiques. Hemisynthèse de la 4′-O-(2-desoxy-l-fucosyl) daunorubicin
Tetrahedron
(1981) - et al.
Drugs ten years later: epirubicin
Ann. Oncol.
(1993) - et al.
Synthesis of daunomycinone
Carbohydr. Res.
(1982) - et al.
Characterization of the Streptomyces peucetius ATCC 29050 genes encoding doxorubicin polyketide synthase
Gene
(1994) - et al.
Conformational analysis of 4-demethoxy- adriamycinone, the first doxorubicin disaccharide analogue to be reported
Carbohydr. Res.
(1997) - et al.
DNA-drug interactions: the crystal structure of d(CGATCG) complexed with daunomycin
J. Mol. Biol.
(1989) - et al.
Synthesis of ring A fluorinated anthracyclines
Tetrahedron
(1996) - et al.
Novel anthracycline disaccharides: effect of the orientation of the second sugar residue on antitumor activity
Ann. Oncol.
(1996) - et al.
Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation
Mol. Pharmacol.
(1996)
New anthracycline disaccharides. Synthesis of l-daunosaminyl-α(1-4)-2-deoxy-lrhamnosyl and of l-daunosaminyl-α(1-4)-2-deoxy-l-fucosyl daunorubicin analogues
J. Chem. Soc. Perkin. Trans. I
(1996)
Doxorubicin, anticancer antibiotics
A doxorubicin disaccharide analog: apoptosis-related improvement of efficacy in vivo
J. Natl. Cancer Inst.
(1997)
Anthracyclinone und Anthracycline (Rhodomycinone, Pyrromycinone und Ihre Glycoside)
Antitumor inhibitors of DNA topoisomerases
Curr. Pharm. Design
(1995)
Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells
Cancer Res.
(1989)
Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV 40 DNA: relationship with DNA binding affinity and cytotoxicity
Biochemistry
(1990)
Cited by (101)
Macrocyclic chemosensors with anthraquinone signaling unit built into ionophore. Experimental and computational studies (part I) - synthesis and effect of proton binding on spectrophotometric and electrochemical properties
2023, Spectrochimica Acta - Part A: Molecular and Biomolecular SpectroscopyAntibiotics in the management of tuberculosis and cancer
2023, Antibiotics - Therapeutic Spectrum and LimitationsThe isolation of water-soluble natural products - challenges, strategies and perspectives
2021, Natural Product ReportsPathway engineering of anthracyclines: Blazing trails in natural product glycodiversification
2020, Journal of Organic ChemistryMetabolic and non-metabolic pathways that control cancer resistance to anthracyclines
2020, Seminars in Cell and Developmental BiologyCitation Excerpt :Doxorubicin (DOX) was derived from DNR by genetic modifications in bacteria [9]. The main difference between DNR and DOX is the presence of a hydroxyl group on the carbon 14 of DOX (Fig. 1B) [8]. Due to its broad spectrum of action on liquid and solid tumors, DOX largely replaced DNR for anticancer therapy, but, unfortunately, heart toxicity remained a strong issue [9].
Hydrogen bonding and protonation effects in amino acids' anthraquinone derivatives - Spectroscopic and electrochemical studies
2019, Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy
Copyright © 1997 Published by Elsevier Inc.